{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:34:44Z","timestamp":1792002884612,"version":"4.4.0"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2024,1,17]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Supplementary nucleic acid amplification testing for\n                    <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                    (NG) is widely used to circumvent specificity problems associated with extragenital sites. Here, we compared different supplementary approaches for confirming NG-positive samples from the cobas 4800 CT\/NG (c4800) and cobas 6800 CT\/NG (c6800) assays using the\n                    <jats:italic>ResistancePlus<\/jats:italic>\n                    GC (RP-GC) assay, which in addition to detecting NG, also predicts ciprofloxacin susceptibility via NG\n                    <jats:italic>gyrA<\/jats:italic>\n                    characterization. Two different nucleic acid extraction techniques were investigated for RP-GC detection; extracts from c4800 (c4800-RP-GC) and MagNA Pure 96 (MP96-RP-GC). NG-positive (\n                    <jats:italic>n<\/jats:italic>\n                    = 300) and -negative (\n                    <jats:italic>n<\/jats:italic>\n                    = 150) samples in cobas PCR media from routine c4800 testing were retrospectively retested with c4800, c6800, c4800-RP-GC, and MP96-RP-GC. Selected samples were also tested with Xpert CT\/NG (Xpert) for discrepant analysis. The\n                    <jats:italic>gyrA<\/jats:italic>\n                    status was compared to ETEST ciprofloxacin susceptibility or non-susceptibility for recovered isolates (\n                    <jats:italic>n<\/jats:italic>\n                    = 63). Extragenital confirmatory rates were higher for MP96-RP-GC (131\/140; 93.6%) compared to c4800-RP-GC (126\/146; 86.3%), albeit not significantly (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.6677). Of 9 samples testing positive by c6800 and negative by MP96-RP-GC, 7\/9 (77.8%) were also negative by Xpert. By contrast, the number of samples returning a valid\n                    <jats:italic>gyrA<\/jats:italic>\n                    status was significantly (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.0003) higher for MP96-RP-GC (270\/293; 92.2%) compared to c4800-RP-GC (245\/298; 82.2%). The overall MP96-RP-GC\n                    <jats:italic>gyrA<\/jats:italic>\n                    status correlated 98.4% (61\/62) with the reported ciprofloxacin sensitive (35\/36; 97.2%) or non-susceptible (26\/26; 100%) phenotype. Improved RP-GC confirmatory rates and reported\n                    <jats:italic>gyrA<\/jats:italic>\n                    status were observed using MP96 nucleic acids compared to c4800 extracts. The data further highlight the ongoing need for NG supplemental testing for oropharyngeal samples.\n                  <\/jats:p>","DOI":"10.1128\/jcm.01039-23","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T09:01:19Z","timestamp":1702371679000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":6,"title":["Maximizing the\n                    <i>Neisseria gonorrhoeae<\/i>\n                    confirmatory rate and the genotypic detection of ciprofloxacin resistance for samples screened with cobas CT\/NG"],"prefix":"10.1128","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5293-9795","authenticated-orcid":true,"given":"Todd M.","family":"Pryce","sequence":"first","affiliation":[{"name":"Department of Clinical Microbiology, PathWest Laboratory Medicine WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia R.","family":"Foti","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, PathWest Laboratory Medicine WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin J.","family":"Haygarth","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, PathWest Laboratory Medicine WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5969-3161","authenticated-orcid":false,"given":"David M.","family":"Whiley","sequence":"additional","affiliation":[{"name":"Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.18.228486"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9020091"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00485-13"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2014-051850"},{"key":"e_1_3_4_6_2","first-page":"E42","article-title":"Review of 2005 public health laboratory network Neisseria gonorrhoeae nucleic acid amplification tests guidelines","volume":"39","author":"Whiley DM","year":"2015","unstructured":"Whiley DM, Lahra MM, National Neisseria Network. 2015. Review of 2005 public health laboratory network Neisseria gonorrhoeae nucleic acid amplification tests guidelines. Commun Dis Intell Q Rep 39:E42\u2013E45.","journal-title":"Commun Dis Intell Q Rep"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1556\/1886.2017.00018"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-020-04004-5"},{"key":"e_1_3_4_9_2","first-page":"358","article-title":"Guidelines for the use and interpretation of nucleic acid detection tests for Neisseria gonorrhoeae in Australia: a position paper on behalf of the public health laboratory network","volume":"29","author":"Smith DW","year":"2005","unstructured":"Smith DW, Tapsall JW, Lum G. 2005. Guidelines for the use and interpretation of nucleic acid detection tests for Neisseria gonorrhoeae in Australia: a position paper on behalf of the public health laboratory network. Commun Dis Intell Q Rep 29:358\u2013365.","journal-title":"Commun Dis Intell Q Rep"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03223-12"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/0956462419886775"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2022-055576"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2013-051021"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00171-3"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2014-051756"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv432"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01909-06"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000230"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3217"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv366"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw864"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00182388"},{"key":"e_1_3_4_23_2","volume-title":"CLSI supplement M100 (ISBN 978-1-68440-104-8 [print]; ISBN 978-1-68440-105 [electronic]","author":"Performance Standards for Antimicrobial Susceptibility Testing","year":"2021","unstructured":"Performance Standards for Antimicrobial Susceptibility Testing. 2021. CLSI supplement M100 (ISBN 978-1-68440-104-8 [print]; ISBN 978-1-68440-105 [electronic]. 31st ed. Clinical and laboratory Standards Institute, USA.","edition":"31"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-022-04519-z"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00806-13"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12902"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2012.192930"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.33321\/cdi.2022.46.52"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002344"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08200-4"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa591"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01039-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01039-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T09:01:20Z","timestamp":1705482080000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.01039-23"}},"subtitle":[],"editor":[{"given":"Daniel D.","family":"Rhoads","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,17]]}},"alternative-id":["10.1128\/jcm.01039-23"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01039-23","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,17]]},"assertion":[{"value":"2023-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01039-23"}}